RxDoctor Payments Data

Joy Rowe, MD

Internal Medicine · Richmond, VANPI 1255383287

Payments from drug & device makers

$815in general payments, 2019–2025

Across 40 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$559
  • Novo Nordisk$55
  • AbbVie$39
  • Astellas Pharma US Inc$33
  • Teva Pharmaceuticals USA, Inc.$27
  • AMAG Pharmaceuticals, Inc.$25
  • plus $78 from 5 others

What the payments were for

  • Food & beverage$79197%
  • Education$253%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$815 in reported general payments places this provider in the 75th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$247,989
Medicare patients
230
Services billed
7,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$78,930
EliquisApixaban26$29,529
FarxigaDapagliflozin Propanediol13$11,724
MounjaroTirzepatide11$11,493
MyrbetriqMirabegron16$10,444
Breo ElliptaFluticasone/Vilanterol16$9,309
NexlizetBempedoic Acid/Ezetimibe11$8,320
SynthroidLevothyroxine Sodium76$6,264
LinzessLinaclotide12$6,205
Rosuvastatin Calcium164$3,200
Eplerenone18$2,960
Febuxostat11$2,927
Valsartan97$2,877
Duloxetine Hcl54$2,627
Atorvastatin Calcium259$2,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$55$78,93040 claims
AbbVieSynthroid, Linzess$39$12,46988 claims
Astellas Pharma US IncMyrbetriq$33$10,44416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →